Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18899511 | METHOD FOR AMELIORATING OR AVOIDING THE ADVERSE EFFECTS OF EXOGENOUS GONADOTROPINS ON REPRODUCTIVE PERFORMANCE | September 2024 | April 2025 | Allow | 7 | 2 | 0 | No | No |
| 18443769 | GDNF FUSION POLYPEPTIDES AND METHODS OF USE THEREOF | February 2024 | April 2025 | Allow | 14 | 1 | 0 | No | No |
| 18529590 | METHODS FOR PROMOTING WOUND HEALINGAND HAIR GROWTH COMPRISING GDNF ADMINISTRATION | December 2023 | March 2025 | Allow | 15 | 1 | 1 | No | No |
| 18138000 | STABLE LIQUID GONADOTROPIN FORMULATION | April 2023 | December 2024 | Allow | 20 | 1 | 0 | No | No |
| 18299458 | FUSION PROTEINS COMPRISING PROGRANULIN | April 2023 | February 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18153944 | TICK CHEMOKINE BINDING PROTEINS FOR USE IN THERAPY AND DIAGNOSIS | January 2023 | November 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17937110 | METHODS OF INCREASING ENDOGENOUS LUTEINIZING HORMONE | September 2022 | May 2025 | Abandon | 32 | 2 | 0 | No | No |
| 17942763 | PSILOCYBIN COMPOSITIONS | September 2022 | April 2025 | Abandon | 31 | 2 | 0 | No | No |
| 17823937 | NEOANTIGEN VACCINES FOR TRIPLE NEGATIVE BREAST CANCER | August 2022 | November 2024 | Allow | 27 | 1 | 1 | No | No |
| 17880962 | BOTULINUM TOXIN FOR USE IN TREATMENT OF AUTISM SPECTRUM DISORDERS | August 2022 | November 2024 | Allow | 27 | 2 | 0 | No | No |
| 17879330 | ASSAYS AND METHODS FOR TARGETED TREATMENT OF HYDROSALPINX | August 2022 | January 2025 | Allow | 29 | 2 | 1 | No | No |
| 17815749 | COMPOSITIONS AND METHODS FOR ANTI-PACAP ANTIBODIES | July 2022 | November 2024 | Allow | 28 | 1 | 1 | No | No |
| 17863028 | Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same | July 2022 | January 2025 | Abandon | 30 | 1 | 1 | No | No |
| 17716754 | METHODS OF REDUCING SYMPTOMS OF OPIOID WITHDRAWAL SYNDROME AND RISK OF RELAPSE TO DRUG SEEKING | April 2022 | June 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17710756 | ASSESSMENT OF PREECLAMPSIA USING ASSAYS FOR FREE AND DISSOCIATED PLACENTAL GROWTH FACTOR | March 2022 | November 2024 | Abandon | 32 | 2 | 0 | No | No |
| 17709305 | HUMAN-DERIVED RECOMBINANT FSH FOR CONTROLLED OVARIAN | March 2022 | September 2024 | Allow | 30 | 2 | 1 | No | No |
| 17696920 | DIMER IMMUNOADHESIN, PHARMACEUTICAL COMPOSTION AND USE THEREOF | March 2022 | June 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17672172 | Methods for Treating Conditions by Restoring Central Nervous System Endocrine Gland Function, and Compositions and Devices for Practicing the Same | February 2022 | March 2025 | Abandon | 37 | 3 | 1 | No | No |
| 17544579 | METHODS FOR TREATING MUSCLE WASTING AND BONE DISEASE USING NOVEL HYBRID ACTRIIB LIGAND TRAP PROTEINS | December 2021 | August 2024 | Allow | 32 | 2 | 1 | No | No |
| 17500741 | ANTI-MERTK ANTIBODIES AND THEIR METHODS OF USE | October 2021 | May 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17600344 | Biomarker Pairs of Preterm Birth | September 2021 | March 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17488906 | METHOD FOR DETECTING IMMINENT CHILDBIRTH | September 2021 | April 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17442593 | MULTISPECIFIC AGENTS FOR TREATMENT OF CANCER | September 2021 | June 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17437065 | ADAM17 BINDING MOLECULES AND USES THEREOF | September 2021 | March 2025 | Allow | 43 | 1 | 0 | No | No |
| 17463876 | DYNAMIC OF SFLT-1 OR ENDOGLiN/PIGF RATIO AS AN INDICATOR FOR IMMINENT PREECLAMPSIA AND/OR HELLP SYNDROME | September 2021 | March 2025 | Allow | 42 | 3 | 0 | No | No |
| 17446369 | METHOD FOR EVALUATING URINE OF A SUBJECT TO ESTIMATE THE FERTILE WINDOW BY EVALUATING FOR THE PRESENCE OF ANALYTES OF ESTROGEN AND PROGESTERONE | August 2021 | August 2024 | Allow | 36 | 3 | 0 | No | No |
| 17432265 | CD33 ANTIBODIES AND METHODS OF USING THE SAME TO TREAT CANCER | August 2021 | February 2025 | Allow | 42 | 1 | 0 | No | No |
| 17429602 | VARIABLE LYMPHOCYTE RECEPTORS THAT TARGET THE BLOOD BRAIN BARRIER AND METHODS OF USE | August 2021 | March 2025 | Allow | 43 | 1 | 0 | No | No |
| 17427208 | MULTISPECIFIC ANTIBODIES HAVING SPECIFICITY FOR TNFA AND IL-17A, ANTIBODIES TARGETING IL-17A, AND METHODS OF USE THEREOF | July 2021 | June 2025 | Allow | 47 | 2 | 0 | No | No |
| 17422353 | SYSTEMS AND METHODS FOR VESICLE CARGO LABELING AND DETECTION | July 2021 | May 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17371436 | AUTOLOGOUS SOMATIC STEM CELL THERAPY, METHOD OF CONTROLLABLE PREPARATION OF THERAPEUTIC COMPOSITION AND PROCEDURE OF ADAPTIVE TREATMENT OF IVF PATIENT | July 2021 | April 2025 | Allow | 45 | 4 | 1 | No | No |
| 17422102 | IN VITRO METHOD FOR THE DIAGNOSIS OR PROGNOSIS OF NEURODEGENERATIVE DISORDERS | July 2021 | February 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17415031 | METHODS OF USING BUTYROPHILIN ANTIBODIES FOR TREATING HIV INFECTION | June 2021 | January 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17311538 | A METHOD OF DETERMINING RISK FOR SKIN CANCER DEVELOPMENT AND SKIN CANCER THERAPEUTIC PREVENTION BY MEASURING PD-1/PD-L1 SIGNALING PATHWAY MEMBERS | June 2021 | May 2025 | Allow | 47 | 2 | 0 | No | No |
| 17311509 | USE OF CD26 AND CD39 AS NEW PHENOTYPIC MARKERS FOR ASSESSING MATURATION OF FOXP3+ T CELLS AND USES THEREOF FOR DIAGNOSTIC PURPOSES | June 2021 | December 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17291858 | COMPOSITIONS AND METHODS OF PROGNOSIS AND CLASSIFICATION FOR PREECLAMPSIA | May 2021 | February 2025 | Allow | 46 | 1 | 1 | No | No |
| 17232513 | PREECLAMPSIA SCREENING DEVICE AND METHODS MEASURING ACTIVIN AND/OR INHIBIN A | April 2021 | December 2024 | Allow | 44 | 4 | 1 | Yes | No |
| 17285314 | COMPOSITIONS AND METHODS FOR CONTROLLED OVARIAN STIMULATION | April 2021 | January 2025 | Allow | 46 | 3 | 0 | No | No |
| 17284302 | DETECTING TUMOR MUTATION BURDEN WITH RNA SUBSTRATE | April 2021 | November 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17282307 | IMMUNOASSAY AND MEASUREMENT REAGENT FOR LEUCINE-RICH ALPHA2 GLYCOPROTEIN | April 2021 | November 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 17044220 | COMPOSITION FOR CONTROLLED OVARIAN STIMULATION | September 2020 | February 2025 | Abandon | 53 | 4 | 1 | No | No |
| 16638179 | METHOD OF IDENTIFYING LAUNDRY MALODOR, MOLDY MALODOR AND/OR SWEAT MALODOR MODULATING COMPOUNDS | February 2020 | December 2024 | Abandon | 58 | 2 | 1 | No | Yes |
| 16603952 | DETECTION OF PREDICTORS OF PREECLAMPSIA | October 2019 | November 2024 | Abandon | 60 | 3 | 1 | No | No |
| 16488935 | Determining Toxicity Risk in CAR T-Cell Therapy | August 2019 | July 2024 | Allow | 59 | 3 | 1 | No | No |
| 16468073 | METHOD OF DIAGNOSIS OF THE AESTHETIC QUALITIES OF THE SKIN | June 2019 | February 2025 | Allow | 60 | 4 | 1 | No | No |
| 16343624 | DOSE DETERMINATION FOR IMMUNOTHERAPEUTIC AGENTS | April 2019 | May 2025 | Abandon | 60 | 6 | 1 | No | No |
| 16242519 | COMPOSITIONS, DEVICES, AND METHODS OF DEPRESSION SENSITIVITY TESTING | January 2019 | September 2024 | Allow | 60 | 6 | 1 | No | Yes |
| 16088785 | METHOD FOR EXTRACORPOREAL TREATMENT OF PREECLAMPSIA AND RELATED DISORDERS | September 2018 | January 2025 | Allow | 60 | 10 | 1 | No | No |
| 15777547 | RECOMBINANT HUMAN C1 ESTERASE INHIBITOR AND USES THEREOF | May 2018 | September 2024 | Allow | 60 | 8 | 1 | No | No |
| 15889261 | Detection and Treatment of Pregnancy Complications Comprising Determining Sialyl Lewis Antigens and Administering hCG | February 2018 | October 2019 | Allow | 20 | 2 | 0 | No | No |
| 15285240 | METHODS AND COMPOSITIONS FOR MANAGING REPRODUCTION | October 2016 | January 2020 | Allow | 39 | 3 | 1 | Yes | No |
| 15079503 | METHOD FOR DIAGNOSING FIBROMYALGIA SYNDROME, AND KIT THEREFOR | March 2016 | August 2018 | Allow | 28 | 2 | 1 | Yes | No |
| 14773677 | PRE-ECLAMPSIA BIOMARKERS | September 2015 | March 2018 | Allow | 30 | 2 | 1 | No | No |
| 14662482 | Pharmaceutical Composition Using Gonadotropin-Releasing Hormone (GNRH) Combined Variants as Immunogen | March 2015 | March 2016 | Allow | 12 | 1 | 0 | No | No |
| 14594772 | SOLUBLE VEGFR-1 VARIANTS FOR DIAGNOSIS OF PREECLAMPSIA | January 2015 | January 2016 | Allow | 12 | 1 | 0 | No | No |
| 14396377 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF STROKE OR OTHER CEREBRAL INJURY | October 2014 | April 2017 | Allow | 29 | 1 | 1 | No | No |
| 14383564 | METHODS OF INHIBITING GONAD MATURATION | September 2014 | August 2017 | Allow | 35 | 2 | 1 | No | No |
| 14233455 | LONG ACTING BIOLOGICALLY ACTIVE LUTEINIZING HORMONE (LH) COMPOUND | April 2014 | January 2016 | Allow | 24 | 1 | 1 | No | No |
| 14353969 | DIAGNOSIS AND TREATMENT OF NEONATAL ENCEPHALOPATHY | April 2014 | August 2019 | Allow | 60 | 7 | 1 | Yes | No |
| 14197988 | Annexin A2 and Tissue Plasminogen Activator For Treating Vascular Disease | March 2014 | November 2015 | Allow | 20 | 2 | 0 | No | No |
| 13954347 | FGF-9 VARIANTS AND METHODS OF USE THEREOF | July 2013 | August 2014 | Allow | 12 | 2 | 0 | No | No |
| 13701472 | Vitronectin:Keratinocyte Growth Factor Chimeras | May 2013 | June 2016 | Allow | 42 | 3 | 0 | No | No |
| 13856035 | METHODS OF TREATING FIBROPROLIFERATIVE DISORDERS OF THE KIDNEY OR REDUCING KIDNEY FIBROSIS | April 2013 | April 2014 | Allow | 12 | 2 | 0 | Yes | No |
| 13509622 | COMPOSITIONS COMPRISING PEDF AND USES OF SAME IN THE TREATMENT AND PREVENTION OF OVARY-RELATED SYNDROMES | November 2012 | October 2014 | Allow | 29 | 2 | 1 | No | No |
| 13647934 | HUMAN CORD BLOOD AS A SOURCE OF NEURAL TISSUE REPAIR OF THE BRAIN AND SPINAL CORD | October 2012 | June 2017 | Allow | 56 | 5 | 1 | Yes | No |
| 13626271 | BLASTOCYST CULTURE SUPERNATANT AS A FERTILITY AGENT IN BLASTOCYST TRANSFER | September 2012 | January 2014 | Allow | 16 | 1 | 0 | No | No |
| 13624365 | Use of the Insulin-Like-Growth Factor 1 Splice Variant MGF for the Prevention of Myocardial Damage | September 2012 | August 2014 | Abandon | 23 | 4 | 1 | Yes | No |
| 13619228 | METHOD OF TREATING FIBROPROLIFERATIVE DISORDERS OF THE HEART AND LUNG | September 2012 | December 2012 | Allow | 3 | 0 | 0 | No | No |
| 13511776 | FIBRONECTIN: GROWTH FACTOR CHIMERAS | August 2012 | March 2015 | Allow | 34 | 4 | 1 | No | No |
| 13439544 | MICRONUTRIENT SUPPLEMENT WITH CALCIUM, VITAMIN D OR CALCIUM & VITAMIN D COMBINATION FOR PREMENSTRUAL/MENSTRUAL RELIEF | April 2012 | March 2015 | Allow | 35 | 4 | 1 | Yes | Yes |
| 13423666 | ANTICALINS | March 2012 | May 2013 | Allow | 14 | 1 | 0 | No | No |
| 13422363 | BRAIN-DERIVED NEUROTROPHIC FACTOR OR NEUROTROPHIN-4/5 TO TREAT PERIODONTAL DISEASES AND PULPAL DISEASES | March 2012 | March 2015 | Allow | 36 | 3 | 0 | No | No |
| 13347823 | FGF-9 VARIANTS AND METHODS FOR USE THEREOF | January 2012 | April 2013 | Allow | 15 | 1 | 1 | No | No |
| 13169922 | METHOD OF IDENTIFYING FETAL ANTIGENS OR CELL SURFACE MARKERS USING PHAGE DISPLAY TECHNOLOGY | June 2011 | September 2014 | Allow | 39 | 3 | 1 | No | No |
| 13121915 | PHARMACEUTICAL COMPOSITION USING GONADOTROPIN - RELEASING HORMONE (GNRH) COMBINED VARIANTS AS IMMUNOGEN | June 2011 | December 2014 | Allow | 45 | 3 | 1 | No | No |
| 13120605 | TREATMENT OF PRETERM LABOR WITH TOLL-LIKE RECEPTOR 9 ANTAGONISTS | June 2011 | October 2014 | Allow | 43 | 2 | 1 | No | No |
| 13114861 | SALMON FOLLITROPIN HORMONE ANALOGS | May 2011 | July 2013 | Allow | 26 | 2 | 1 | No | No |
| 13053751 | CONTRACEPTIVE PEPTIDES DERIVED FROM THE VENOM OF THE SPIDER LATRODECTUS MIRABILIS, NUCLEOTIDE SEQUENCES TO TRANSFORM A MICROORGANISM TO PRODUCE SAID PEPTIDES; METHODS TO OBTAIN THE PEPTIDES; PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF AND USE THEREOF | March 2011 | October 2014 | Allow | 42 | 1 | 1 | No | No |
| 12941629 | LHRH - ANTAGONISTS IN THE TREATMENT OF FERTILITY DISORDERS | November 2010 | June 2015 | Allow | 55 | 1 | 1 | No | No |
| 12896094 | ECTOPIC PREGNANCY TREATMENT | October 2010 | June 2014 | Allow | 44 | 2 | 1 | No | No |
| 12893764 | A METHOD FOR PREPARING RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR CYSTEINE MUTEINS | September 2010 | August 2014 | Allow | 47 | 4 | 1 | No | Yes |
| 12888051 | HCG FORMULATIONS FOR ACHIEVING WEIGHT LOSS | September 2010 | November 2013 | Allow | 37 | 2 | 1 | Yes | No |
| 12816475 | ANTIBODIES THAT SPECIFICALLY BIND BETA-LIKE GLYCOPROTEIN HORMONE POLYPEPTIDES AND HETERODIMERS THEREOF | June 2010 | May 2012 | Allow | 23 | 2 | 0 | Yes | No |
| 12793386 | Synthetic Chimeric Proteins Comprising Epidermal Growth Factor and Vitronectin | June 2010 | June 2014 | Allow | 49 | 4 | 1 | No | No |
| 12670099 | PEPTIDES DERIVED FROM PLASMINOGEN ACTIVATOR INHIBITOR-1 AND USES THEREOF | April 2010 | April 2013 | Allow | 39 | 1 | 1 | No | No |
| 12731387 | SOLUBLE EPIDERMAL GROWTH FACTOR RECEPTOR ISOFORMS | March 2010 | July 2011 | Allow | 15 | 1 | 1 | Yes | No |
| 12709920 | IMPLANTABLE PUMP FOR PROTEIN DELIVERY FOR OBESITY CONTROL BY DRUG INFUSION INTO THE BRAIN | February 2010 | May 2012 | Allow | 27 | 2 | 0 | No | No |
| 12695907 | SERPINE2 AS A BIOMARKER FOR IGA NEPHROPATHY | January 2010 | January 2012 | Allow | 23 | 1 | 1 | No | No |
| 12654809 | ANTICALINS | January 2010 | December 2011 | Allow | 23 | 2 | 1 | No | No |
| 12615035 | GRANULOCYTE COLONY STIMULATING FACTOR FOR THE TREATMENT OF AN OVULATION DISORDER CAUSED BY LUTEINIZED UNRUPTURED FOLLICLE | November 2009 | January 2012 | Allow | 27 | 2 | 0 | No | No |
| 12446884 | LIPID MICROPARTICLE GROWTH FACTOR FORMULATIONS | June 2009 | August 2016 | Allow | 60 | 3 | 1 | No | No |
| 12416435 | FGF VARIANTS AND METHODS FOR USE THEREOF | April 2009 | October 2011 | Allow | 30 | 1 | 1 | No | No |
| 12291639 | HORMONE NORMALIZATION THERAPY COMPRISING ADMINISTRATION OF AROMATASE INHIBITOR, FOLLICLE STIMULATING HORMONE, LUTEINIZING HORMONE, HUMAN CHORIONIC GONADOTROPIN, GONADOTROPIN HORMONE RELEASING HORMONE AND/OR PROGESTERONE | November 2008 | August 2011 | Abandon | 33 | 3 | 2 | No | No |
| 12298829 | INVESTIGATION OF MUCOSA DRYNESS CONDITIONS | October 2008 | August 2011 | Allow | 33 | 1 | 2 | No | No |
| 12206445 | SOLUBLE EPIDERMAL GROWTH FACTOR RECEPTOR ISOFORMS | September 2008 | September 2010 | Allow | 24 | 1 | 2 | No | No |
| 12092006 | METHOD FOR PURIFYING FSH OR A FSH MUTANT | August 2008 | August 2013 | Allow | 60 | 2 | 1 | No | No |
| 12089445 | TRANSDERMAL DELIVERY SYSTEM FOR TREATING INFERTILITY | April 2008 | November 2012 | Allow | 55 | 3 | 1 | No | No |
| 11574367 | METHODS AND COMPOSITIONS RELATING TO ALZHEIMER'S DISEASE | March 2008 | October 2013 | Allow | 60 | 4 | 1 | No | No |
| 12041370 | METHOD FOR DIAGNOSIS OF ALZHEIMER'S DISEASE WITH DETERMINATION OF LASP-1 IMMUNOREACTIVITY | March 2008 | March 2010 | Allow | 25 | 1 | 0 | No | No |
| 11967469 | MUTEINS OF PLACENTAL GROWTH FACTOR TYPE I, PREPARATION METHOD AND APPLICATION THEREOF | December 2007 | June 2010 | Allow | 29 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BORGEEST, CHRISTINA M.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 33.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BORGEEST, CHRISTINA M works in Art Unit 1675 and has examined 136 patent applications in our dataset. With an allowance rate of 82.4%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 42 months.
Examiner BORGEEST, CHRISTINA M's allowance rate of 82.4% places them in the 48% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by BORGEEST, CHRISTINA M receive 2.35 office actions before reaching final disposition. This places the examiner in the 80% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by BORGEEST, CHRISTINA M is 42 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +18.4% benefit to allowance rate for applications examined by BORGEEST, CHRISTINA M. This interview benefit is in the 65% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 30.6% of applications are subsequently allowed. This success rate is in the 52% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 57.4% of cases where such amendments are filed. This entry rate is in the 80% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 71.4% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 14.7% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.4% of allowed cases (in the 80% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.